Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$56.0 million.

  • Regenxbio's Cash from Operations fell 3800.59% to -$56.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.3 million, marking a year-over-year increase of 4332.47%. This contributed to the annual value of -$173.1 million for FY2024, which is 2073.29% up from last year.
  • As of Q3 2025, Regenxbio's Cash from Operations stood at -$56.0 million, which was down 3800.59% from -$49.3 million recorded in Q2 2025.
  • Regenxbio's 5-year Cash from Operations high stood at $341.5 million for Q4 2021, and its period low was -$80.9 million during Q1 2023.
  • Its 5-year average for Cash from Operations is -$23.8 million, with a median of -$45.5 million in 2024.
  • As far as peak fluctuations go, Regenxbio's Cash from Operations soared by 76525.03% in 2021, and later plummeted by 11152.92% in 2022.
  • Regenxbio's Cash from Operations (Quarter) stood at $341.5 million in 2021, then tumbled by 111.53% to -$39.4 million in 2022, then fell by 3.53% to -$40.8 million in 2023, then rose by 22.41% to -$31.6 million in 2024, then tumbled by 76.95% to -$56.0 million in 2025.
  • Its Cash from Operations was -$56.0 million in Q3 2025, compared to -$49.3 million in Q2 2025 and $33.6 million in Q1 2025.